How Trademark Lawsuits Are Tackling Fake Merchandise

By: Teagan Raffenbeul

Counterfeit products have existed for thousands of centuries, with counterfeit currency dating back to 3300-2000 BC. Over time, counterfeiting has grown significantly, with its economic cost estimated to exceed trillions of dollars. As e-commerce has grown, so too has the availability of counterfeit products, including fake merchandise claiming to be endorsed by musical artists. Online marketplaces like Amazon and Etsy have enabled individuals to create and sell products using images of or related to famous individuals. 

In 2023, a fan of country singer Luke Combs created and sold tumblers adorned with Comb’s face on Amazon. The fan, Nicol Harness, sold eighteen of her Combs-themed tumblers, earning only $380. Nonetheless, she was included in a mass lawsuit filed against more than 200 online entities selling unauthorized Combs merchandise. Harness was ordered to pay $250,000 in damages, and her Amazon account was frozen – all before she had notice of the anti-counterfeiting lawsuit. Regardless of whether Harness knew she was infringing on Combs’ intellectual property rights, the products were still counterfeit and could be subject to lawsuits for violating an artist’s intellectual property rights. 

Anti-Counterfeiting Enforcement

Two federal statutes primarily govern anti-counterfeiting enforcement in the United States. The Lanham Act provides civil remedies, while the Trademark Counterfeiting Act of 1984 imposes criminal penalties for violations of the anti-counterfeiting provisions in the Lanham Act. Due to various impracticalities of criminal enforcement, such as timing constraints, trademark owners typically turn to civil trademark infringement lawsuits for relief. 

Counterfeit merchandise is deemed “counterfeit” because it infringes on a valid, registered trademark owned by an artist or another party. A trademark is a symbol that indicates the source of a product to purchasers. Trademarks may present themselves in the form of names, logos, colors, or symbols. For musical artists, their trademarks signal to fans that they endorse the product and officially license it. When an artist’s trademark appears on products they did not create or endorse, it can mislead and confuse fans and consumers into believing the artist is the actual source of the product, even when they are not. Even if a product contains a disclaimer stating the merchandise is merely inspired by the artist, it does not automatically protect the merchandise from receiving a cease-and-desist letter or facing a counterfeit lawsuit. Artists will often strategically choose which cases to litigate, balancing the negative publicity from suing fan-made merchandise against the necessity of taking action against enough infringing products to protect their trademark rights. Factors such as the similarity of names and products, as well as how well-known the infringed trademark is, are usually considered, with direct copies of artists’ own merchandise often purposely targeted.

Anti-counterfeiting lawsuits have a higher standard than the “likelihood of confusion” standard used in traditional trademark infringement cases. The Lanham Act defines a counterfeit mark as “a spurious mark which is identical to or substantially indistinguishable from a registered mark.” This requires a higher degree of similarity, with marks needing to be “identical” to be successful in a counterfeit lawsuit. 

Additionally, when filing a civil counterfeiting case, most plaintiffs will request an ex parte temporary restraining order (TRO). These TROs may be granted without prior notice to the alleged counterfeiter and they immediately remove the counterfeit items from the market. The TROs also prevent the alleged counterfeiters from disposing of or destroying evidence of the counterfeit items.

“SAD Schemes”

Due to the increase of e-commerce in the last decade, an influx of counterfeit merchandise has become easily accessible online. In response, several U.S. law firms, particularly in Chicago, have begun initiating mass anti-counterfeiting trademark lawsuits, targeting hundreds of merchandise sellers simultaneously. The uniformity found between anti-counterfeiting enforcement suits has led to these types of lawsuits being labeled by some people as “SAD Schemes.”

These mass lawsuits have been coined “SAD Schemes” or “Schedule A Defendants” schemes because plaintiffs typically file the complaint separately from a sealed Schedule A attachment. The plaintiff usually identifies a group of online vendors whose listed products infringe on their intellectual property rights and includes them on a Schedule A attachment. The complaint refers to these vendors as “defendants listed on a Schedule A,” and the judge then seals the Schedule A, keeping the defendants’ identities anonymous. The complaint itself generally includes a few factual allegations that are not particularized to any one defendant. Following this, plaintiffs frequently request an ex parte TRO to freeze the defendants’ assets and activity in the marketplace. 

These lawsuits are often filed by large brands such as Nike and Ray-Ban, however recently they have increasingly been applied to fight counterfeit merchandise. In 2022, the rock band Nirvana sued approximately 200 different sites for selling counterfeit products. The following year, pop artist Harry Styles filed a massive Schedule A trademark suit to combat the increasing quantity of counterfeit merchandise populating online stores. 

Downsides of “SAD Schemes” 

SAD Schemes are often filed under the presumption that the “counterfeiters” are difficult to locate and trace due to the nature of e-commerce. As a result, judges frequently permit email service. This provides plaintiffs a significant advantage, as many defendants are often not aware they have been legally served. Many defendants never see the email, as was the case in the Combs lawsuit, where the email was sent to the fan’s junk mail. Some defendants have said they have mistaken it for spam mail or an extortion attempt, and therefore disregard the email. Due to issues such as these, judges generally do not permit email service in ordinary cases. However, in SAD Schemes, when cases are filed under the presumption the alleged counterfeiters are anonymous online merchants who are difficult to track down, judges allow it. As a result, defendants’ funds are often frozen, and many default judgments have been rendered without any opposition from the defendants.

Lawyers utilizing SAD Schemes typically follow a standardized template with minimal factual allegations allowing them to easily “clone-and-revise” the complaint for future lawsuits. This streamlined approach, combined with the ability to target hundreds of defendants at once, saves plaintiffs significant time and money while also enabling lawyers to quickly process multiple cases. SAD Schemes can unfold in just a few days, resulting in a somewhat lucrative business for intellectual property firms. By leveraging Schedule A forms that keep defendants’ identities hidden and relying on the fact that most alleged counterfeiters are either unaware of the lawsuit or unwilling to fight back due to the expensive and time-consuming nature of the lawsuits, these lawyers and law firms have begun to turn it into a volume business. Over the past decade, this field has seen the number of Schedule A anti-counterfeiting trademark lawsuits rise from 105 to 938, with over 600,000 defendants having been sued.

SAD Schemes are a relatively new type of lawsuit. There is limited precedent, and district courts have taken various approaches in interpreting the statutory language and applying relevant terminology such as “counterfeit” and “counterfeiting.” This has resulted in some inconsistencies and confusion among existing case law. In the future, we can likely expect to see a continued rise in counterfeit merchandise and a rise in lawsuits by these artists to protect their intellectual property rights, hopefully providing more clarity and information on how anti-counterfeiting enforcement is executed.

More Money, More Problems: Legal Implications of Private Equity in College Sports

By: Tavis McClain

In the new era of college sports that allows players to profit from their name, image, and likeness (“NIL”), growth is rapid and more entities seek industry involvement. Initially, in 2021 when NIL became legal, college athletes could not be paid by the universities directly. Recently, a District Court Judge granted preliminary approval for a settlement that would allow universities to pay their athletes directly. Seeing a lucrative investment opportunity, private equity firms have recently begun investing in college sports. For many years, the NCAA has rejected investment from outside sources, such as private equity firms. College sports is heading toward becoming a semi-professional industry direction, due to a combination of NIL factors and the NCAA allowing private equity firms to invest in college sports. This blog will provide a brief history of why investment in college sports has changed, and cover the various legal issues that may arise with private equity firms’ investment in college sports including antitrust law, regulatory/compliance concerns, and labor law implications. 

History 

In October 2024, a settlement was reached in House v. NCAA that required the NCAA and its power conferences to pay out $2.8 billion in backpay for former athletes over the past ten years. The settlement further requires that athletic departments find up to $30 million annually between revenue sharing with athletes and reduced NCAA distributions. This has provided the opportunity for private equity firms such as Red Bird Capital and Weatherford Capital to negotiate with universities in need of funding.

Antitrust 

A key issue is antitrust law, which seeks to promote fair competition and prevent monopolistic practices. When private equity firms invest in multiple college sports programs, there is a possibility that these investments could reduce the level of competition among institutions, creating antitrust concerns. Private equity firms would be wise to invest in established programs that can generate their desired returns. If private equity firms control several top athletic programs, they could potentially consolidate power over broadcasting rights or negotiate favorable media contracts for those programs. This would reduce opportunities for smaller schools to compete on equal footing, potentially creating an unfair advantage for schools backed by private equity. This is an even greater concern because of the TV deals/streaming rights that the SEC and Big Ten have–the most lucrative TV deals by a sizable margin. If private equity firms invest in schools from these conferences, it could exacerbate the talent disparity between conferences. Because private equity firms could own stakes in multiple teams, this could create conflicts of interest and hinder competition. It’s been reported that JPMorgan Chase has had negotiations with Florida State and other schools to capitalize on the promising opportunity to have stakes in multiple teams. The legal issues could stem from accusations of price-fixing or anti-competitive conduct, especially if the investments result in monopolies or oligopolies within the college sports market.

Regulatory/Compliance Issues

In addition to antitrust concerns, private equity investments in college sports may also raise issues related to compliance with existing state and federal regulations. Because college sports are typically governed by both federal law and the regulatory frameworks of state governments, private equity firms looking to invest in these programs must navigate a complicated landscape of rules and oversight. A specific example is the recent changes in NIL legislation. With college athletes now able to profit from NIL, there is increased potential for private equity firms to leverage their investments by facilitating NIL deals. In the absence of clear federal regulation governing how these transactions are handled, private equity firms could exploit loopholes, leading to further legal and ethical complications. The most important NIL law in the state of Washington is Senate Bill 5913, now RCW 42.52.807. Private equity firms could run into legal issues if they violate the act, such as the failure to comply with the disclosure requirement. Legal questions will arise around whether private equity firms are required to comply with these state regulations.

Labor Law Implications 

There has been significant movement toward the recognition of student-athletes as employees rather than amateurs. In light of recent legal developments such as the NCAA v. Alston case and the broader push for NIL rights, the role of private equity in shaping the economic and employment landscape of college athletes is becoming more controversial. 

Private equity involvement may result in legal challenges regarding whether student-athletes should be classified as employees. This could entitle college athletes to collective-bargaining rights, the rights of employees to negotiate with their employer as a group through a representative, which the NCAA has opposed. If college athletes were to attain collective bargaining power, they could further leverage their power as employees and argue for more favorable policies. Private equity firms, with their financial influence, may also advocate for arrangements that limit student-athletes’s control over their image or impose longer-term contracts, which could come under scrutiny from legislators and agencies. By placing limitations on students’ control over their image and imposing long-term contracts, private equity firms can maximize their profits. Long-term contracts could lead private equity firms to profit from college athletes later in their careers. For example, Big League Advantage, an investment firm, sought to enforce a contract that entitled the company to 15% of a college athlete’s pretax earnings for the rest of his career. These types of contracts in college sports are unprecedented and there may be legal challenges to the enforceability of these contracts.

Conclusion

The legal landscape in college sports is constantly evolving. Lawyers will play a pivotal role in navigating the complex challenges that are presented that span across multiple areas of law. Stay tuned to see how private equity’s investment changes college sports.

#WJLTA #sports #competition #athletes #NIL

Cyrus’ Flowers Copyright Suit: Simply the Latest Celebrity Copyright Lawsuit or a Changing Precedent in Who Can Bring Copyright Lawsuits?

By: William H. Kronblat

In today’s music landscape it may feel painfully obvious that some artists incorporate, mimic, or replicate parts of previous songs—even those that are not their own—on the way to producing top charting hits. While this practice may feel commonplace it still presents a very relevant and contemporary copyright-centric legal question as to whether that copying was allowed, who has ownership of the musical composition used, and what remedies are allowed if someone were to unlawfully copy a copyrighted work. Moreover, if someone in the music industry wants to bring a copyright lawsuit forward, who is legally able to do so? This particular question has come to the forefront of one the latest celebrity music copyright lawsuits in which Tempo Music has sued Miley Cyrus, alleging she ripped off Bruno Mars’ “When I Was Your Man” in her hit song “Flowers”. 

The Leadup to the Lawsuit:

In January of 2013 Bruno Mars Released his hit song “When I Was Your Man” as a single. A few years later in 2020, Tempo Music Investments acquired a share of the copyright to the song from one its four writers, Philip Lawrence. Roughly a decade after Mars released his single, in January of 2023, Miley Cyrus released her hit song “Flowers”. It quickly topped charts  and was “streamed more than 2 billon times on Spotify.” The popular song also garnered  Cyrus a Grammy award for Record of the Year, and a Grammy award for Best Pop Solo Performance. As of June of 2024, Cyrus’ song made history by holding the top spot on various music charts. Then in September of 2024, Tempo Music Investments filed a civil lawsuit against Cyrus. The lawsuit did not list the song’s other three songwriters as plaintiffs. 

The Heart of the Lawsuit and Cryus’ Motion to Dismiss:

Tempo Music Investments accused Cyrus of copying or mimicking parts of Mars’ song including key elements like the melody, harmony, and chorus. Tempo Music Investments claimed that     “based on the combination and number of similarities between the two recordings that “Flowers” would not exist without “When I Was Your Man.” In addition to Cyrus, the lawsuit names “Flowers” other songwriters as defendants along with Sony Music Publishing and various distributors like Amazon, Walmart, and Target. In the lawsuit, Tempo Music Investments is seeking damages and to bar Cyrus from performing and distributing “Flowers”. 

Cyrus and her legal team responded by filing a motion to dismiss arguing that the lawsuit should be thrown out. In the motion to dismiss, Cyrus’ legal team asserts that the “allegedly copied elements are random, scattered, unprotected ideas and musical building blocks.” However, the more intricate argument that Cyrus’ legal team advances is that Tempo Music Investments does not have standing to bring the lawsuit. They claim that in the 9th Circuit, where the lawsuit was brought, there is precedent that a copyright holder must have exclusive rights over the copyright under Section 501(b) to confer standing. Furthermore, they claim that Tempo Music Investments lacks exclusive rights over the copyright because they only have a partial interest from Philip Lawrence—one of the four songwriters of “When I Was Your Man”— and do not have the interests from the other “When I Was Your Man” songwriters. 

A New Precedent Out of the Ninth Circuit?

This motion to dismiss hearing is set to take place on January 27th of 2025 in the US District Court for the Central District of California. Tempo’s lawyers have already noted that they adamantly disagree with Cyrus’ standing to sue argument noting that it is “blackletter law” any one owner of copyright could bring a lawsuit without the other owners. Nonetheless, Cyrus’ motion to dismiss has opened the doors for a new precedent on who can bring a copyright lawsuit (more specifically in the Ninth Circuit). Some lawyers and legal scholars believe that if Cyrus’ standing claim is successful it may create a “problematic” precedent. If her argument is successful, it could make it increasingly difficult to enforce a copyright without every partial owner’s participation.  This could have significant ramifications for the licensing of intellectual property and would diminish the value of licensing fractional shares of copyrights. 

Ultimately, this case could fundamentally change how intellectual property contracts are done in the entertainment industry and cast a shadow on numerous previous license deals because it may render partial ownership of IP worthless. The ability to enforce your intellectual property is a fundamental aspect of intellectual property law. If this precedent is established, those who purchase partial ownership of a copyright will be left powerless to enforce their newly purchased copyright, and they will be at the mercy of the other copyright owners as to whether they can go after potential infringers. As noted above, this case is still in district court and would require a decision on appeal to officially set any kind of precedent. However, even if this case does not go up on appeal it may still present the foundation for a new legal argument others may attempt to adopt. In the meantime, this will be an important case for any intellectual property owner or intellectual property lawyer to keep an eye on.  

#Miley Cyrus, #Copyright, #Flowers Lawsuit

AI Doctors: Muddying The Waters of Patient Privacy?

By: Nirmalya Chaudhuri

Introduction

In November 2024, a study reported that ChatGPT acting on its own performed better at diagnosing diseases than trained doctors in the US, with a reported 90% success rate. While singing paeans of Artificial Intelligence (AI) in almost every field of human activity has now become par for the course, the possibility of the rise of “AI doctors” raises important questions relating to patient privacy and, in particular, the larger doctor-patient relationship.

Crisis of Confidentiality: From Ethics to Law

The delicate nature of the doctor-patient relationship was beautifully expounded in the eighteenth-century writings of John Gregory and Thomas Percival, two pioneering figures in the field of medical ethics. As Gregory and Percival noted, doctors inevitably gain access to the private lives of their patients, and this naturally requires them to exercise great discretion in dealing with the personal information entrusted to them. In certain fields, such as psychotherapy, this is all the more important, which has led to a strong movement  (and its acceptance by some courts in the US) to carve out a“psychotherapist-patient privilege” exception to the Federal Rules of Evidence governing confidential communications.

Today, the narrative on this issue may well shift from a purely ethical viewpoint into a more legalistic perspective on data protection and privacy. It is, therefore, not surprising that the General Data Protection Regulation (GDPR) in the European Union, classifies “health data” as one of the categories of “sensitive personal data”, to which heightened standards and safeguards apply. When patients directly interact with an “AI doctor,” sensitive personal data relating to not only one’s health but also one’s private life, would be disclosed. 

In the absence of strong legal regulations for processing such data, it is possible that patient data could be used for purposes other than providing patient care. The concerns are exacerbated by the fact that generative AI may “learn” or “train” itself using such sensitive patient data, leading to outcomes that are both inconceivable and perhaps undesirable for the patient. While a possible counter-argument would be that explicit consent of the patient would be a prerequisite before any health data is divulged to the AI doctor, there is a wealth of secondary literature that questions whether the patients truly know what they are consenting to instead of treating consent like a routine, box-ticking exercise. 

Judicial opinion

Case law on this topic is non-existent, presumably because the issue of “AI doctors” is novel. However, in the past, courts have sought to tread cautiously as far as divulging patient records to third parties is concerned. The Ohio Supreme Court, in Biddle v. Warren General Hospital, went so far as to suggest that unauthorized disclosure of patient records to a third party amounted to an independent tort by itself, irrespective of how that information was utilized by the third party. It is, of course, true that the court was dealing with a case where the patients had not consented to disclosure of their data. In the UK case of Source Informatics, the Court of Appeal allowed the passing of patient records to a third party. However, in that case, it is worth noting that the patient data was anonymized before disclosure, thus making the argument relating to data protection that much weaker. 

These cases would prove to be of limited application if and when the debate on AI doctors reaches the stage of litigation. In these circumstances, the courts would then be deciding whether patients can consent to the disclosure of non-anonymized sensitive personal data to an AI entity and the extent to which the AI tool can use that information. 

Conclusion

In the absence of a federal data protection law in the US, there is a possibility that legal regulation of the wide-ranging use of AI doctors would be State-specific and fragmented. Even more importantly, a lack of legal regulation would raise serious concerns about whether AI doctors are indeed “practicing” medicine, which would directly determine whether they will be bound by professional obligations that are ordinarily applicable to doctors, such as the preservation of confidentiality of patient data. A possible solution to this problem could lie in a conclusive determination of the legal status of AI doctors, and the techno-legal accountability standards like purpose limitation and data minimization that they would be subject to. While AI can potentially lead to great benefits in medical science, one must ensure that confidentiality, privacy, and protection of personal data are not allowed to be sacrificed at the altar of convenience and diagnostic efficiency.

Pharma-Pirates: How Patent Law Enables the Theft of Indigenous Knowledge

By: Alex Okun

Health and wellness are a key driver of consumer spending in the United States (US). The US pharmaceutical market is expected to exceed $1 trillion by 2030, and the value of its “wellness” industry (which includes everything from fitness equipment to psychotherapy) has skyrocketed to nearly $1.8 trillion. As life expectancy in America has remained relatively low and as Americans have become increasingly reluctant to seek synthetic remedies, market leaders have seized upon the trend toward natural health treatments. However, many companies have attempted to patent traditional medicines as if they were cutting-edge drugs, usually at the expense of the indigenous peoples who discovered them.

Patents

In the US, the owner of a utility patent has the right to prohibit anyone from selling their invention for 20 years from the date the patent is filed. To obtain patent protection, the invention must be “novel” and advance beyond existing technology in a way that would not be obvious to others in the industry. Patent examiners usually check global patent databases and trade publications to determine the state of existing technology (or “prior art”), and then assess the “obviousness” of the claimed invention in context. Even if granted, however, a patent is vulnerable to legal challenge if a third party disputes either the novelty or the obviousness of the invention. If a plaintiff can establish that the patented invention was either already in use or was merely an obvious advance over existing methods, the patent will be revoked. 

Biopiracy

“Biopiracy” is defined as patenting an indigenous group’s traditional knowledge or genetic resources for commercial gain. Perhaps the most infamous case was in 1995 when two US researchers patented the use of turmeric as an antimicrobial treatment for open wounds. They were granted the patent, but a group of Indian scientists sued to have it canceled because turmeric has been used in medicine for thousands of years. The patent was successfully canceled, but international biopiracy threatens traditional knowledge in medicine, foods, and industrial materials. Attempts at fighting back have generally been successful only in the most egregious instances, or when national governments have intervened on the people’s behalf in US courts.

Soon after the revocation of the turmeric patent, the Indian government took proactive measures by assembling a database of traditional medicine texts and translating them into English. This was consequential particularly for US law because evidence proving that an invention was used before being patented (an essential step to cancel a patent) must be available in English. When an invention has already been patented abroad this process is relatively simple because the US is obligated by treaty to recognize patents issued in most other countries. The US has not, however, ratified the treaties requiring the recognition of foreign discoveries that were never patented. As a result, US law only recognizes evidence of foreign “public use” of an invention if provided in the 9 months following a patent’s issuance. This places a significant burden on remedies and inventions based on traditional knowledge, which is often codified in oral traditions or ancient texts without readily available translations.

Global Guardrails

The Convention on Biological Diversity (“CBD”), which went into effect in 1993, was the first legally binding treaty designed to “conserve biological diversity, to sustainably use its components and to share equitably the benefits arising from the use of genetic resources.” Although the treaty recognized the rights of indigenous people to their knowledge, a far more significant advance toward effective legal protections came from the Nagoya Protocol in 2014. The Nagoya Protocol was intended to “ensure that traditional knowledge associated with genetic resources” is accessed only with the informed consent of the indigenous community from which those resources originated. It also created a framework for a “benefit-sharing mechanism” that would remunerate indigenous communities for the commercial gains resulting from the use of their traditional knowledge. The Access and Benefit-Sharing Clearing House provides information on the laws, procedures, and model contracts for benefit-sharing agreements for all of the Protocol’s member states. 142 nations have now ratified the CBD and Nagoya Protocol, including most of the European Union. However, the United States has neither joined the Convention nor participated in the benefit-sharing that Nagoya was intended to facilitate.

A key gap in the Nagoya Protocol’s provisions was that it did not address the issuance of patents. As a result, patent applicants are not obligated under the treaty to disclose whether traditional knowledge went into their inventions. However, 30 countries came to a solution in May 2024 with the Treaty on Intellectual Property, Genetic Resources, and Associated Traditional Knowledge (“GRATK”). Ratifying states must require patent applicants to disclose any source(s) of traditional knowledge underlying their claimed inventions, and the countries or indigenous groups from which the knowledge originates. While it does not mandate its members to reject applications due to traditional knowledge sources, the disclosure requirement will enable greater transparency in the patent examination process. GRATK also calls for a global system of traditional knowledge databases, such that national patent offices can more readily assess whether an application truly contains a “novel” invention. This would create a more efficient, robust patent examination and allow indigenous advocates to challenge patents without expending excessive resources to collect the requisite evidence. The World Intellectual Property Organization (“WIPO”), which administers GRATK, already administers a database of global patents and now maintains an extensive list of traditional knowledge databases worldwide. Although GRATK is only binding on its 38 signatories as of December 2024, experts are hopeful that it will soon be ratified by major economies like Australia, Brazil, and India.

Conclusion

In the context of traditional medicine, there is not necessarily an inherent conflict between social justice and innovation. The discoveries of indigenous people can fill the existing gaps in modern medicine and serve the needs of patients who either do not want or cannot use existing treatments. However, three key needs must be met for the system to be just: attribution of source, informed consent, and sharing the profits from these cures with the people who created them. All three issues are addressed by GRATK (attribution) and Nagoya (consent and benefit-sharing), and the growing web of traditional knowledge databases is empowering advocates to challenge biopiracy when it occurs. Although it is unclear whether the new administration will seek US accession to either treaty, patent law in its current form has been effectively used by advocates to combat biopiracy at its source. Unless the USPTO commits to more proactively examining traditional knowledge sources, this fight will remain dependent on the availability of traditional knowledge resources and the vigilance of indigenous advocates.